The Financial Transactions and Reports Analysis Centre of Canada (FINTRAC) announced it was imposing a $4.4 million administrative monetary penalty on Binance for failing to register and report large ...

NEW YORK--(BUSINESS WIRE)--Anti-money laundering tech startup First AML has raised US$5.4 million in a Series A funding round led by US-based Bedrock Capital, with support from existing investors ...

Ziftomenib is approved for relapsed or refractory acute myeloid leukemia with an NPM1 mutation, offering a new targeted treatment option. The approval is based on the KOMET-001 trial, which showed ...

Revumenib demonstrates significant efficacy in R/R AML with NPM1m, KMT2Ar, and NUP98r, showing high response rates and tolerability. The AUGMENT-101 study reports a 26% CR/CRh rate in NPM1-mutated AML ...

A recent study shows a regimen of low-dose homoharringtonine, cytarabine, and G-CSF (HAG) is an effective and promising treatment for pediatric patients with AML.

Median Overall Survival (OS) of 15 months for subjects with complete remission (n=8) Median OS of 2 nd Line efficacy evaluable population of 12 months (n=9) Median OS of Intent to Treat population (1L ...

Homoharringtonine-Based Induction Regimen Improved the Remission Rate and Survival Rate in Chinese Childhood AML: A Report From the CCLG-AML 2015 Protocol Study It will be important to confirm this ...

Patients with acute myeloid leukemia (AML) often reach complete remission, but relapse rates remain high. Next-generation sequencing enables the detection of molecular minimal residual disease in ...